Navigation Links
Tumors evolve rapidly in a childhood cancer, leaving fewer obvious tumor targets
Date:1/20/2013

An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Contrary to expectations, the scientists found relatively few recurrent gene mutationsmutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now refocused on how neuroblastoma tumors evolve in response to medicine and other factors.

"This research underscores the fact that tumor cells often change rapidly over time, so more effective treatments for this aggressive cancer will need to account for the dynamic nature of neuroblastoma," said study leader John M. Maris, M.D., director of the Center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP).

Striking the peripheral nervous system, neuroblastoma usually appears as a solid tumor in a young child's chest or abdomen. It comprises 7 percent of all childhood cancers, but causes 10 to 15 percent of all childhood cancer-related deaths. Neuroblastoma is notoriously complex, with a broad number of gene changes that can give rise to the disease.

Maris headed the multicenter research collaborative, the TARGET (Therapeutically Applicable Research to Generate Effective Treatments) initiative, which released its findings today in Nature Genetics. This largest-ever study genomic study of a childhood cancer analyzed DNA from 240 children with high-risk neuroblastomas. Using a combination of whole-exome, whole-genome and transcriptome sequencing, the study compared DNA from tumors with DNA in normal cells from the same patients.

Researchers at CHOP and other centers previously discovered neuroblastoma-causing mutations, such as those in the ALK gene. In the subset of patients carrying this mutation, oncologists can provide effective treatments tailored to their genetic profile.

"A few years ago, we thought we would be able to sequence the genome
'/>"/>

Contact: Rachel Salis-Silverman
salis@email.chop.edu
267-426-6063
Children's Hospital of Philadelphia
Source:Eurekalert

Page: 1 2

Related biology news :

1. Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools
2. TGen leads new National Institutes of Health study of brain tumors
3. A single stem cell mutation triggers fibroid tumors
4. Cancerous tumors deliver pro-metastatic information in secreted vesicles
5. Breast cancer drug could halt other tumors
6. Researchers identify proteins that indicate which kidney tumors are most likely to spread
7. Cancer stem cells isolated from kidney tumors
8. Study uncovers mechanism used by BRCA1 to suppress tumors
9. Leading evolutionary scientist to discuss how genome of bacteria has evolved
10. Excessive worrying may have co-evolved with intelligence
11. Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
(Date:6/17/2015)... Germany , June 17, 2015 ... QIA) today launched new Investigator ® STR assay kits ... the United States . The new genetic fingerprint ... genomic markers (short tandem repeats or STRs) for DNA matching. ... the quality of DNA in each sample, a novel QIAGEN ...
(Date:6/17/2015)... 17, 2015  Crossmatch™, a leading provider of ... U.are.U ® 4500 fingerprint readers have been ... Inc., a San Jose, CA ... security, improve accountability and reduce fraud at the ... identity confirmation for employee sign in and transaction ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... to play a crucial role in the manufacture of a ... researchers led by scientists at the National Institute of Child ... , The protein is known as mBDNF, which stands for ... of NICHD researchers had shown that mBDNF is essential for ...
... licensed software that will give scientists a ... known as Rosetta, predicts how proteins fold, ... biomedical researchers.,UW Tech Transfer's Digital Ventures licensed ... Systems Biology (ISB), a non-profit,research organization. The ...
... of Washington TechTransfer,recently licensed software that will ... against disease.,The software, known as Rosetta, predicts ... to biological and biomedical researchers.,UW Tech Transfer's ... the Institute for Systems Biology (ISB), a ...
Cached Biology News:Researchers Uncover Key Step In Manufacture of Memory Protein 2Researchers find how protein allows insects to detect and respond to pheromones 2UW's Rosetta software to unlock secrets of many human proteins 2
(Date:7/1/2015)... , ... July 01, 2015 , ... The next-generation sequencing ... key market segments, including the molecular diagnostics industry. BCC Research reveals in its new ... NGS-based tests, lower test costs, and a growing need for better diagnostics as part ...
(Date:7/1/2015)... -- Isagenix International, a leading global health and wellness ... and three Bronze Stevie® Awards at the 2015 Annual ... this month.The American Business Awards ... the U.S. "Winning is a tremendous ... cultivating talent, creating a unified team, and crafting the ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... to combat pathogen transmission. CTI’ new Medical Joysticks have an impermeable molecular ... now have an operator control device that will increase healthcare worker safety and ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - Resverlogix ... of common shares of Resverlogix have approved the ... Eastern Capital Limited of 5,600,000 units at a ... Placement"), each unit being comprised of one common ... aggregate proceeds of approximately CAD$15 million; and (ii) ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... Oct. 1 SoluLinK, Inc., a leader ... kits, announces the,introduction of its newest product, ... kit includes all the components for the ... kit features SoluLinK,s,patented sulfo-ChromaLink Biotin linker, a ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ... focused on,endocrine therapy and oncology, today reported ... second efficacy trial of its Phase 3 ... enlargement of the,prostate, with its flagship product ...
... TOLEDO announces the launch of the FBRM® C35, ... , ... ... -- Using probe-based FBRM (Focused Beam Reflectance Measurement) ...
Cached Biology Technology:SoluLinK Introduces New One-Shot ChromaLink(TM) Biotin Antibody Labeling Kit with Built-in Biotin Quantification. 2AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 4Monitor Granule Growth in Process with the FBRM C35 2
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
Rabbit polyclonal to NCoR2, prediluted ( Abpromise for all tested applications). entrezGeneID: 9612 SwissProtID: Q9Y618...
Goat polyclonal to Nebraska Calf Diarrhea Virus (FITC) ( Abpromise for all tested applications). Antigen: Bovine (Nebraska Calf Diarrhea Virus)....
Phospho- (Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb...
Biology Products: